From The Editor

  1. The Compounded Risk Of Early-Stage Biopharma Licensing Deals 6/25/2020

    A new paper illustrating big pharma’s tendency to backfill phase three failures by rushing into new licensing deals underscores a risk to emerging biotechs.

  2. Mechanistic Action: Genesis Of A Biologics Pipeline? 6/17/2020

    Cue Biopharma President & CSO Anish Suri, Ph.D. tells us why a partnership with The University Of Oxford to visualize the mechanistic action of molecules at the immunological synapse could provide insights that guide future drug discovery and development strategy.

  3. Precision Medicine In Practice 6/16/2020

    Precision medicine is bringing biopharma closer to the patient. The Christ Hospital Health Network Director Of Precision Medicine Dr. Burns Blaxall discusses why clinical-level practitioners are the key link between biopharmas and patients, and how AI is helping to define the practice.

  4. Securing Biotech Funding When Economies Get Wild 6/12/2020

    There’s disruption on the startup biotech money trail. Navigating it requires a pliable strategy. Here, multi-time founder and investor Bert Liang shares insight on raising funds during volatile times. 

  5. A New Cost Paradigm For CAR Cell Therapies? 6/12/2020

    Hear from Acepodia CEO Sonny Hsiao about his company's claims that its proprietary approach to conjugating novel natural killer cells could reduce the cost of cellular therapeutics.

  6. View From Tokyo: Rise Of The “Values” Chain 5/15/2020

    The Wuhan coronavirus outbreak has brokered a virulent "value" chain debate around the world, including a global CDMO's CEO situated in Tokyo. 

  7. The Real Threat To Biopharma Supply Chains: Bioprocessing Materials 5/12/2020

    The COVID-19 induced risk to biopharma is not a shortage of pharmaceutical ingredients. It’s the constricting supply of consumable materials and equipment necessary to produce therapies from them. Mike Piccarreta, Partner at Kearney, offers an outlook and practical advice on supply stabilization in this BioProcess Online exclusive. 

  8. ILC Therapeutics’ Interferon Alpha 14 Joins The COVID-19 Fight 5/5/2020

    The Glasgow-based emerging biopharma recently tapped veteran biotech leader Alan Walker as CEO as it moves ahead with two therapeutic candidates, an rIFN alpha14 focused on early-stage COVID-19 infection and a tick-derived Evasin targeting late-stage COVID-19 ARDS patients.

  9. A COVID-19 Vaccine, Outsourcing, And Made In The USA 4/27/2020

    That’s an unwieldy title for an editorial. But we’ll bundle those three components quickly, thanks to U.S.-based GeoVax Labs CEO David Dodd. He's the quintessential professional to assist readers in assessing and contemplating current and future realities.

  10. Santiago: Leading The Chilean Biotech Revolution 4/23/2020

    Biotechs are surging in Chile, fertilized by a deep academic foundation, ample funding, plentiful low-cost laboratory space, and a collaborative global research environment. We caught up with Cristian Hernandez-Cuevas, the man behind the mission.